ADVERTISEMENT

Blood Disorders

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.

2025’s Therapy Area Growth Drivers And Brakes: Part Two

2025’s Therapy Area Growth Drivers And Brakes: Part Two

The second instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on blood malignancies, skin conditions and generalized cardiovascular disease.

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.

FDA Evaluating Safety Of Plastic Syringes From China, May Prevent Their Import To The US

FDA Evaluating Safety Of Plastic Syringes From China, May Prevent Their Import To The US

The US FDA is advising the public that certain plastic syringes from China could fail, leak, or break. If necessary, the agency may prevent Chinese syringes from entering the US.

FDA Receives Thousands Of Opinions On Proposal To Regulate LDTs As Comment Period Comes To A Close

FDA Receives Thousands Of Opinions On Proposal To Regulate LDTs As Comment Period Comes To A Close

As the US FDA works to finalize new regulation of lab-developed tests, it must consider more than two thousand comments that have poured into the agency since the proposed rule was published in October. The comment period closes Monday.

News We’re Watching: More Class I Recalls, FDA Expands TAP, Guardant Appeals Patent Verdict, And More

News We’re Watching: More Class I Recalls, FDA Expands TAP, Guardant Appeals Patent Verdict, And More

This week, the US FDA labelled several recalls class I, approved an at-home diagnostic for chlamydia and gonorrhea, and announced the expansion of its TAP pilot program. Guardant Health also announced it would appeal a verdict in a patent suit against the company and AdvaMed voiced its continued support for pending breakthrough device legislation.

News We’re Watching: Expiring Guidance Documents; Multi-Cancer Diagnostic Meeting Set; 510(k)s For BD And Smileyscope

News We’re Watching: Expiring Guidance Documents; Multi-Cancer Diagnostic Meeting Set; 510(k)s For BD And Smileyscope

This week, the US FDA announced that several pandemic-era guidance documents are no longer in effect; an FDA advisory committee meeting on multi-cancer detection (MCD) diagnostics was scheduled; and both a needle-free blood collection device and the first VR treatment for pain and anxiety landed FDA clearances.

Blood Irradiation Devices May Be Class III, FDA Panel Says

Blood Irradiation Devices May Be Class III, FDA Panel Says

The FDA radiological devices advisory panel said that there wasn’t enough evidence backing the use of irradiation to prevent metastasis in the blood of cancer patients, especially given the treatment’s known risks.

News We’re Watching: Boston Scientific's POLARx Is Approved,  IABP Recalls, Intricon Opens Facility in Costa Rica

News We’re Watching: Boston Scientific's POLARx Is Approved, IABP Recalls, Intricon Opens Facility in Costa Rica

This week, FDA cleared Terumo's Reveos automated whole blood processing system, Abbott adds the Alinity-h hematology system to its comprehensive lab diagnostics lineup, Movano moves forward with "smart ring" technology, and more.

Fostering a Culture of Innovation, From Evolutionary To Revolutionary

Fostering a Culture of Innovation, From Evolutionary To Revolutionary

Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.